SCI时时刷

search
+
Zastaprazan: First Approval
Zastaprazan: First Approval
Zastaprazan (JAQBO®) is a next-generation potassium-competitive acid blocker being developed by Onconic Therapeutics,...
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease
ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation ...
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model
ALZ-801/valiltramiprosate is an oral, small-molecule inhibitor of beta-amyloid (Aβ) aggregation and oligomer formatio...
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews
Temporomandibular disorders (TMDs) encompass several conditions that cause pain and impair function of the masticatory mus...
Sotatercept: First Approval
Sotatercept: First Approval
Sotatercept (sotatercept-csrk; WINREVAIRTM) is an activin signalling inhibitor that is being developed by Merck and Co., I...
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough
Refractory chronic cough is a disabling disease with very limited therapeutic options. A better understanding of cough pat...
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Monoclonal antibodies targeting interleukin (IL)-5 pathways have revolutionized the treatment expectations for eosinophili...
Aprocitentan: First Approval
Aprocitentan: First Approval
Aprocitentan (TRYVIO™) is a once-daily oral dual endothelin A (ETA) and B (ETB) receptor antagonist developed by Ido...
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned
The development of new medicines for systemic lupus erythematosus (SLE) has not addressed unmet clinical need, with only t...
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis
Although dual antiplatelet therapy (DAPT) improves the outcomes of patients undergoing percutaneous coronary intervention ...
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions
Depression during the first year postpartum (postpartum depression) impacts millions of women and their families worldwide...
Drugs in Development to Treat IgA Nephropathy
Drugs in Development to Treat IgA Nephropathy
IgA nephropathy is a common glomerulonephritis consequent to the autoimmune response to aberrant glycosylated immunoglobul...
Ensitrelvir Fumaric Acid: First Approval
Ensitrelvir Fumaric Acid: First Approval
Ensitrelvir fumaric acid (Xocova®) is an oral SARS-CoV-2 main protease inhibitor developed by Shionogi for the treatm...
Tegileridine: First Approval
Tegileridine: First Approval
Tegileridine (艾苏特) is a small molecule μ-opioid receptor biased agonist developed by Jiangsu Hen...
Resmetirom: First Approval
Resmetirom: First Approval
Resmetirom (Rezdiffra™) is an oral thyroid hormone receptor-β (THR-β) agonist being developed by Madrigal ...
Cefepime/Enmetazobactam: First Approval
Cefepime/Enmetazobactam: First Approval
Cefepime/enmetazobactam (EXBLIFEP®), an intravenous (IV) antibacterial fixed-dose combination of a 4th generation cep...
Crovalimab: First Approval
Crovalimab: First Approval
Crovalimab (派圣凯®; PiaSky) is a humanized, anti-complement component C5 (anti-C5) recycling monoc...
Bimekizumab: A Review in Psoriatic Arthritis
Bimekizumab: A Review in Psoriatic Arthritis
Although several biological disease-modifying antirheumatic drugs (bDMARDs), including interleukin (IL)-17A inhibitors, ar...
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
The COVID-19 pandemic has resulted in over 772 million confirmed cases, including nearly 7 million deaths, according to th...
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease
Dry eye disease (DED) can arise from a variety of factors, including inflammation, meibomian gland dysfunction (MGD), and ...
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Among the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sa...
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Dr...
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders
The sirtuin family is a heterogeneous group of proteins that play a critical role in many cellular activities. Several deg...
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Topical ruxolitinib 1.5% cream (Opzelura®), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in ...
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree®...
The Pharmacological Landscape for Fatty Change of the Pancreas
The Pharmacological Landscape for Fatty Change of the Pancreas
The quest for medications to reduce intra-pancreatic fat deposition is now quarter a century old. While no specific medica...
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease
Perfluorohexyloctane ophthalmic solution (Miebo®) is a single-entity, water-, steroid- and preservative-free, first-i...
Dimdazenil: First Approval
Dimdazenil: First Approval
Dimdazenil (Junoenil®) is a small-molecule, oral, partial positive allosteric modulator of the gamma-aminobutyric aci...
Danicopan: First Approval
Danicopan: First Approval
Danicopan (Voydeya®) is an oral complement factor D inhibitor that is being developed by Alexion AstraZeneca Rare Dis...
Iptacopan: First Approval
Iptacopan: First Approval
Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatmen...
阅读更多
format_indent_increase